Pacira BioSciences, Inc. - Common Stock (NQ:PCRX)

36.42 +0.08 (+0.22%)

Delayed Quote Updated: 4:00 PM EDT, Oct 23, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Pacira BioSciences, Inc. - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stocks That Hit 52-Week Lows On Monday ↗

January 23, 2023

On Monday, 12 stocks hit new 52-week lows.

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

January 10, 2023

Tuesday's session saw 16 companies set new 52-week lows.

Via Benzinga

Pacira BioSciences Reports Preliminary Unaudited Total Revenue for 2022 of $666.8 Million

January 05, 2023

EXPAREL average daily sales 104% of the prior year for the fourth quarter and 107% of the prior year for the month of December

From Pacira BioSciences

Via GlobeNewswire

Pacira BioSciences's Return On Capital Employed Insights ↗

November 23, 2022

Via Benzinga

Pacira Touts Positive Data From EXPAREL Study In Toe Correction Surgery ↗

September 21, 2022

Via Benzinga

Pacira Posts Topline Data From Knee Surgery Study With Its Flagship Pain Management Drug ↗

September 07, 2022

Via Benzinga

Pacira BioSciences' Return On Capital Employed Overview ↗

August 08, 2022

Via Benzinga

Pacira BioSciences to Present at the 41st Annual J.P. Morgan Healthcare Conference

January 04, 2023

From Pacira BioSciences

Via GlobeNewswire

JetBlue Airways, Pacira BioSciences And Some Other Big Stocks Moving Lower On Tuesday ↗

December 13, 2022

U.S. stocks traded slightly higher, with the Nasdaq Composite gaining around 70 points on Tuesday. Here are some big stocks recording losses in today’s session.

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

December 13, 2022

On Tuesday, 49 companies hit new 52-week lows.

Via Benzinga

Pacira BioSciences Reports Preliminary Net Product Sales of $57.5 Million for November 2022

December 13, 2022

EXPAREL sales were 99 percent and unit volumes were 104 percent of November 2021

From Pacira BioSciences

Via GlobeNewswire

Stocks That Hit 52-Week Lows On Wednesday ↗

November 16, 2022

On Wednesday, 70 companies set new 52-week lows.

Via Benzinga

Pacira BioSciences Reports Preliminary Net Product Sales of $54.9 Million for October 2022

November 14, 2022

From Pacira BioSciences

Via GlobeNewswire

Pacira BioSciences to Present at Two Healthcare Conferences in November

November 08, 2022

From Pacira BioSciences

Via GlobeNewswire

Pacira BioSciences: Q3 Earnings Insights ↗

November 03, 2022

Pacira BioSciences (NASDAQ:PCRX) reported its Q3 earnings results on Thursday, November 3, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Pacira BioSciences Reports Third Quarter 2022 Financial Results

November 03, 2022

From Pacira BioSciences

Via GlobeNewswire

Pacira to Report Third Quarter 2022 Financial Results on Thursday November 3, 2022

October 20, 2022

From Pacira BioSciences

Via GlobeNewswire

Pacira BioSciences Reports Preliminary Third Quarter 2022 Revenue of $167.5 Million

October 13, 2022

-- EXPAREL average daily sales 109% of the prior year for the third quarter and 113% of the prior year for the month of September --

From Pacira BioSciences

Via GlobeNewswire

Pacira Pharmaceuticals Stock Shows Rising Relative Strength ↗

October 07, 2022

On Friday, Pacira Pharmaceuticals stock got an upgrade to its Relative Strength (RS) Rating, from 69 to 73.

Via Investor's Business Daily

Important Biotech Catalysts For September 7, 2022 - End Of The Day Summary ↗

September 07, 2022

Via Benzinga

Pacira BioSciences: Q2 Earnings Insights ↗

August 03, 2022

Pacira BioSciences (NASDAQ:PCRX) reported its Q2 earnings results on Wednesday, August 3, 2022. Here's what investors need to know about the announcement.

Via Benzinga

Pacira to Report Second Quarter 2022 Financial Results on Wednesday August 3, 2022

July 27, 2022

From Pacira BioSciences

Via GlobeNewswire

Needham Maintains Buy Rating for Pacira BioSciences: Here's What You Need To Know ↗

June 15, 2022

Needham has decided to maintain its Buy rating of Pacira BioSciences (NASDAQ:PCRX) and lower its price target from $84.00 to $76.00. Shares of Pacira BioSciences are trading up 3.85% over the last 24...

Via Benzinga

10 Biggest Price Target Changes For Wednesday ↗

June 15, 2022

Jefferies raised Tapestry, Inc. (NYSE: TPR) price target from $30 to $45. Tapestry shares rose 2.2% to close at $31.60 on Tuesday.

Via Benzinga

Pacira Pharmaceuticals Stock Shows Improved Relative Price Performance; Still Shy Of Benchmark ↗

June 08, 2022

On Wednesday, Pacira Pharmaceuticals stock got an upgrade to its Relative Strength (RS) Rating, from 66 to 75.

Via Investor's Business Daily

Regeneron Pharmaceutical Stock Sees RS Rating Jump To 82 ↗

June 08, 2022

Looking for the best stocks to buy? Focus on those with rising relative price strength, such as Regeneron Pharmaceutical stock.

Via Investor's Business Daily

Vertex Pharmaceuticals Receives Composite Rating Upgrade ↗

May 24, 2022

The IBD SmartSelect Composite Rating for VRTX stock increased from 94 to 96 Tuesday, a sign of strong fundamentals.

Via Investor's Business Daily

Pacira BioSciences's Return on Invested Capital Overview ↗

May 20, 2022

Pulled from Benzinga Pro data, Pacira BioSciences (NASDAQ:PCRX) posted Q1 earnings of $6.83 million, an increase from Q4 of 233.1%. Sales dropped to $157.99 million, a 0.76% decrease between quarters.

Via Benzinga

Gilead Stock Earns Rating Upgrade After Quick Turnaround ↗

May 19, 2022

A Relative Strength Rating upgrade for Gilead stock shows improving technical performance. Will it continue?

Via Investor's Business Daily

Pacira BioSciences: Q1 Earnings Insights ↗

May 04, 2022

Pacira BioSciences (NASDAQ:PCRX) reported its Q1 earnings results on Wednesday, May 4, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.